BioNTech (BNTX) Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.

Which has stronger valuation and earnings, GSK or BNTX?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$37.71B	1.94	$6.13B	$1.54	22.96
BioNTech	$3.04B	9.53	$1.01B	-$2.10	-57.56

Is GSK or BNTX a better dividend stock?

GSK pays an annual dividend of $1.48 per share and has a dividend yield of 4.2%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.3%. GSK pays out 96.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioNTech pays out -72.9% of its earnings in the form of a dividend.

Is GSK or BNTX more profitable?

GSK has a net margin of 7.97% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 50.62% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	7.97%	50.62%	11.54%
BioNTech	-15.16%	-2.35%	-2.05%

Which has more volatility & risk, GSK or BNTX?

GSK has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Does the media favor GSK or BNTX?

In the previous week, GSK had 4 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for GSK and 11 mentions for BioNTech. BioNTech's average media sentiment score of 0.74 beat GSK's score of 0.12 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
BioNTech	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer GSK or BNTX?

GSK currently has a consensus price target of $43.25, suggesting a potential upside of 22.33%. BioNTech has a consensus price target of $142.72, suggesting a potential upside of 18.06%. Given GSK's higher possible upside, equities research analysts plainly believe GSK is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.67
BioNTech	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Does the MarketBeat Community favor GSK or BNTX?

GSK received 681 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.13% of users gave GSK an outperform vote while only 46.05% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
GSK	Outperform Votes 821 57.13%	Underperform Votes 616 42.87%
BioNTech	Outperform Votes 140 46.05%	Underperform Votes 164 53.95%

Do institutionals and insiders have more ownership in GSK or BNTX?

15.7% of GSK shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

GSK beats BioNTech on 15 of the 21 factors compared between the two stocks.